Trials / Completed
CompletedNCT00545012
A Safety and Efficacy Follow-up Study With Levetiracetam in Children (4-17 Years Old) Suffering From Absence Seizures
A 30-month Safety and Efficacy Follow-up Study With Levetiracetam at Individualized Optimal Dose in Children (4-17 Years Old at Inclusion) Suffering From Typical Absences in Childhood Absence Epilepsy (CAE) or Juvenile Absence Epilepsy (JAE)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 4 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
This long-term open label follow-up trial gave pediatric subjects suffering from typical absences in CAE or JAE the opportunity to continue levetiracetam treatment after participation in the pilot study (study N162) or the double-blind study (study N163). Safety and efficacy data were obtained.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levetiracetam |
Timeline
- Start date
- 2000-05-01
- Primary completion
- 2003-05-01
- Completion
- 2003-05-01
- First posted
- 2007-10-16
- Last updated
- 2013-09-17
Source: ClinicalTrials.gov record NCT00545012. Inclusion in this directory is not an endorsement.